Results of EMPA-REG OUTCOME trial for Jardiance (empagliflozin) show risk reductions for type 2 diabetes consistent across age groups- Boehringer/ Eli Lilly

New analyses showed risk reductions were consistent across age groups for cardiovascular (CV) outcomes, including CV death, with Jardiance (empagliflozin), from Boehringher/Eli Lilly, compared with placebo when added to standard of care in adults with type 2 diabetes (T2D) and established CV disease. Data examined the effect of treatment with Jardiance by age in the EMPA-REG OUTCOME trial. Trial participants were grouped based on their age at baseline: under 65 years, from 65 to 74, and 75 years and older. Consistent reduction in the risk of CV death was seen independent of age groups. Further analysis demonstrated similar consistency by age group in reducing risk for hospitalization for heart failure, as well as for the combination of hospitalization for heart failure or CV death. Adverse events were consistent with the known safety profile of Jardiance.

Furthermore, the reduction in risk for CV events did not differ among sub-groups of adults in the EMPA-REG OUTCOME trial based on their LDL ("bad") cholesterol levels at baseline (below 70 mg/dL; 70 to 85 mg/dL; 85 to 100 mg/dL; 100-115 mg/dL; and more than 115 mg/dL). The risk reduction with Jardiance was consistent across the LDL sub-groups (indicated by a lack of statistical interaction by sub-group) for the combination of CV death, non-fatal heart attack or non-fatal stroke, as well as for the individual outcomes of CV death, hospitalization for heart failure and death from any cause. These data were presented at the American Diabetes Association (ADA) 76th Scientific Sessions.